Overlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesityOverlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesity
A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in postmenopausal women with obesity. It also raises the possibility that treatment of these aggressive breast cancers could be improved with the addition of weight-loss drugs known as GLP-1 receptor agonists.
Doctors are seeing more aggressive breast cancer in younger women than expectedDoctors are seeing more aggressive breast cancer in younger women than expected
Younger women are being diagnosed with breast cancer more often than screening guidelines anticipate. Many of these cancers are invasive and harder to treat, especially in those under 40. After analyzing 11 years of data, researchers found that this age group makes up a steady and significant share of diagnoses. The results support a stronger push for earlier risk evaluation.
AI Model Outperformed Density Assessment in Stratifying Breast Cancer RiskAI Model Outperformed Density Assessment in Stratifying Breast Cancer Risk
(MedPage Today) — An image-only artificial intelligence (AI) model recently authorized by the FDA conferred more precise risk stratification in predicting the 5-year risk of breast cancer compared with radiologist-based breast density assessments…
New Guidelines on GLP-1 Drugs for Obesity ReleasedNew Guidelines on GLP-1 Drugs for Obesity Released
(MedPage Today) — GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle interventions, but global accessibility must be improved, the World Health Organization (WHO) concluded. The WHO made two recommendations… (MedPage Today) — GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle Read More
WHO recommends Ozempic-style weight loss drugs for obesityWHO recommends Ozempic-style weight loss drugs for obesity
Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, and economic burden. Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, Read More
World Health Organization recommends GLP-1 drugs for obesityWorld Health Organization recommends GLP-1 drugs for obesity
The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for patients. The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for Read More
World Health Organization recommends GLP-1 drugs for obesityWorld Health Organization recommends GLP-1 drugs for obesity
The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for patients. The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for […]
WHO recommends use of GLP-1 drugs for obesityWHO recommends use of GLP-1 drugs for obesity
WHO recommends use of GLP-1 drugs for obesity WHO recommends use of GLP-1 drugs for obesity
WHO issues guidance on GLP-1 drugs for obesityWHO issues guidance on GLP-1 drugs for obesity
The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability. The World Health Organization issued new guidelines recommending the use of GLP-1 drugs for adults with obesity and called for action on manufacturing and affordability.
STAT+: Pharmalittle: We’re reading about a U.K.-U.S. tariff deal on drugs, a Lilly price cut for Zepbound, and moreSTAT+: Pharmalittle: We’re reading about a U.K.-U.S. tariff deal on drugs, a Lilly price cut for Zepbound, and more
Good morning, everyone, and nice to see you again after we took an extended holiday break. Of course, we are now playing a game of catch-up as we attempt to rifle through thousands of emails and digest the flood of news over the past several days. To cope, we are firing up the trusted coffee Read More